Treating Moderate to Severe Atopic Dermatitis with Ivarmacitinib
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 5th, 2025
|
The inflammation and itching characteristic of atopic dermatitis are driven primarily by the cytokines IL-4, IL-13, and IL-31. Current therapies target these cytokines or their downstream signaling proteins, such as the Janus kinase (JAK) family; however, their efficacy remains limited and adverse effects are common. To address these challenges, Jiangsu Hengrui Pharmaceuticals funded a study to evaluate the efficacy and safety of ivarmacitinib, a selective JAK inhibitor, for the treatment of atopic dermatitis.
This phase 3 clinical trial enrolled 336 participants with a mean age of 31 years, all diagnosed with moderate-to-severe atopic dermatitis based on the Hanifin and Rajka criteria. At baseline, approximately 60% of patients had an Investigator Global Assessment (IGA) score of 3, indicating perceptible dull-red erythema with possible lichenification, while the remainder had a more severe score of 4, denoting widespread bright-red erythema. The average Eczema Area and Severity Index (EASI) score was around 28 on a 0–72 scale.
Participants were randomly assigned to receive either placebo or ivarmacitinib at daily doses of 4 mg or 8 mg. Like other JAK inhibitors such as baricitinib and upadacitinib, ivarmacitinib acts through inhibition of the JAK/STAT signaling pathway, but it demonstrates higher selectivity for JAK1 with minimal activity against JAK2, potentially lowering the risk of hematologic side effects such as neutropenia and anemia.
After 16 weeks of treatment, ivarmacitinib significantly improved disease severity: approximately 40% of patients achieved an IGA score of 0 or 1, compared with only 9% in the placebo group. Similarly, about 60% of those receiving ivarmacitinib achieved at least a 75% reduction in EASI score, versus 21.6% with placebo. The incidence of adverse events was comparable across all groups, and no hematologic abnormalities were observed in patients treated with ivarmacitinib. Longer-term studies are needed to assess sustained efficacy and safety and to compare ivarmacitinib with other approved therapies for atopic dermatitis.
This phase 3 clinical trial enrolled 336 participants with a mean age of 31 years, all diagnosed with moderate-to-severe atopic dermatitis based on the Hanifin and Rajka criteria. At baseline, approximately 60% of patients had an Investigator Global Assessment (IGA) score of 3, indicating perceptible dull-red erythema with possible lichenification, while the remainder had a more severe score of 4, denoting widespread bright-red erythema. The average Eczema Area and Severity Index (EASI) score was around 28 on a 0–72 scale.
Participants were randomly assigned to receive either placebo or ivarmacitinib at daily doses of 4 mg or 8 mg. Like other JAK inhibitors such as baricitinib and upadacitinib, ivarmacitinib acts through inhibition of the JAK/STAT signaling pathway, but it demonstrates higher selectivity for JAK1 with minimal activity against JAK2, potentially lowering the risk of hematologic side effects such as neutropenia and anemia.
After 16 weeks of treatment, ivarmacitinib significantly improved disease severity: approximately 40% of patients achieved an IGA score of 0 or 1, compared with only 9% in the placebo group. Similarly, about 60% of those receiving ivarmacitinib achieved at least a 75% reduction in EASI score, versus 21.6% with placebo. The incidence of adverse events was comparable across all groups, and no hematologic abnormalities were observed in patients treated with ivarmacitinib. Longer-term studies are needed to assess sustained efficacy and safety and to compare ivarmacitinib with other approved therapies for atopic dermatitis.